Abstract
The receptor for advanced glycation end products (RAGE) transduces the impact of the products of nonenzymatic glycation and oxidation of proteins, the advanced glycation end products, proinflammatory ligands S100/calgranulins and high mobility group box 1. The ligand families of RAGE accumulate in the vasculature in diabetes and are enriched in atherosclerotic lesions, both in human and animal models. Experimentation in animal models of both Type 1 and 2 diabetes reveals that antagonism of the ligand–RAGE axis suppresses the development and progression of vascular and inflammatory cell perturbation in the diabetic milieu; key processes linked to acceleration of atherosclerosis and exaggerated neointimal expansion consequent to arterial injury. We propose that blockade of RAGE may represent an effective target for therapeutic intervention in diabetes and its cardiovascular complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
